Effect of a Transcutaneous Electrical Nerve Stimulation (TENS) Device on Overall Facial Appearance

NCT01740440 | Completed Phase 4 Results

• 1 other identifier: SRG-BMR Face01
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Safety and clinical performance of the BMR Face device (manufactured by Bio-Medical Research)

Conditions

Ageing

Keywords

Healthy females

Outcome Measures

Primary Outcomes (1)

• Evaluate Overall Facial Improvement Assessed Live by the Investigator and Subjects Using the Global Aesthetic Improvement Scale (GAIS) at 12 Weeks Compared to Baseline.

  Evaluate the efficacy of the Efficacy will be assessed by overall facial improvement assessed live by the Investigator and a subject assessment of facial appearance including the Global Aesthetic Improvement Scale (GAIS). The Global Aesthetic Improvement Scale is a five-grade subjective test. The physician and patient independently describe the degree of improvement in facial appearance. Possible responses were (1) Significantly marked improvement, (2) marked improvement, (3) moderate improvement, (4) slight improvement, (5) no improvement. For reporting of outcomes, the higher the GAIS value, the greater the improvement (Range 0-4).

  12 weeks

Secondary Outcomes (2)

• To Evaluate Overall Facial Improvement Assessed Live by the Investigator and Subjects Including the Global Aesthetic Improvement Scale (GAIS) at 6 Weeks Compared to Baseline

  6 weeks

• To Evaluate the Subject's Satisfaction With BMR Face Treatment at 6 Weeks and 12 Weeks (Subject Self- Assessment).

  6 weeks, 12 weeks

Study Arms (1)

BMR Face treatment

OTHER

BMR Face treatment used once a day for 12 weeks

Device: BMR Face

Interventions

BMR Face DEVICE

BMR Face used in accordance with manufacturer IFU

BMR Face treatment

Eligibility Criteria

• Age: 35 Years - 55 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subjects who are able to give voluntary, written informed consent to participate in this study and from whom consent has been obtained including HIPAA authorization
• Subjects who are healthy females between 35 and 55 years of age
• Subjects with a Body Mass Index (BMI) between 15-35 kg/m2 (light underweighted to light obese)
• Subjects may have all skin types
• Subjects with age related skin laxity in the treatment area
• Subjects who agree not to have any procedures affecting facial volume (any fillers or fat transfer) for the duration of the study
• Subjects who agree not to have any other procedures affecting skin quality (microdermabrasion, resurfacing, peels, lasers, acne treatments, etc.) for the duration of the study
• Subjects who agree to make no changes in their existing skincare regime during the study period
• Subjects who agree to avoid excessive sun radiation or use appropriate sun protection with SPF 30 or higher
• Subjects who agree not to alter their diet for the duration of the study
• Subjects who understand this study and are able to follow study instructions and are willing to attend the required study visits
• Subjects who agree to be photographed for the purposes of the study and give consent for these photographs to be used in marketing advertisements where their identity will not be concealed in these photographs

You may not qualify if:

• Subjects who are pregnant, planning to become pregnant or breastfeeding. A urine pregnancy test will be done to rule out pregnancy.
• Subjects of child-bearing potential who are not using an approved method of birth control (oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence)
• Subjects who cannot understand or are not willing to comply with the requirements of the study
• Subjects who have any dermatologic conditions including acne, rosacea, eczema, psoriasis, severe sun damage or scars within the treatment area
• Subjects who have any known cancer including skin cancers (Basal Cell Carcinoma, Squamous Cell Carcinoma and Melanoma)
• Subjects with a history of heart disease or stroke
• Subjects who have any active implanted medical devices (pacemaker, pump etc)
• Subjects having any metal implants. Dental implants and fillings are allowed as well as piercings as long as they are not in the treatment area.
• Subjects who have used a tanning bed in the past four weeks or plan to use a tanning bed for the duration of the study
• Subjects who are HIV positive
• Subjects who have had systemic corticosteroid therapy in the past 6 months
• Subjects who have had a facial dermabrasion, chemical peel, laser, or IPL treatment in the past 6 months
• Subjects who have used botulinum toxin, hyaluronic acid, collagen, fat injections and /or other methods of skin augmentation (enhancement with injected or implanted material) in the past 6 months
• Subjects who have had ablative resurfacing procedure, brow lift, blepharoplasty or face lift in treated area in the past 12 months
• Subjects who have had any other surgery in treated area in the past 12 months

Sponsors & Collaborators

• Bio-Medical Research, Ltd.: lead

Study Sites (1)

Sadick Research Group

New York, New Jersey, 10075, United States

Location

Results Point of Contact

• Title: Gary Rainsford
• Organization: BioMedical Research Ltd

grainsford@bmr.ie

0035391774361

Study Officials

• Neil Sadick, Dr

  Sadick Research Group

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 21, 2012
• First Posted: December 4, 2012
• Study Start: November 1, 2012
• Primary Completion: April 1, 2013
• Study Completion: April 1, 2013
• Last Updated: June 30, 2016
• Results First Posted: March 24, 2016

Record last verified: 2016-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)